DOI: 10.1055/s-00000017

Experimental and Clinical Endocrinology & Diabetes

Referenz

Zelniker TA, Wiviott SD, Raz I. et al.
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials.

Lancet 2019;
393: 31-39

Bibliographische Angaben herunterladen

Aufrufen in:
Aufrufen in: